» Articles » PMID: 27086364

Clinical and Socioeconomic Impact of Moderate-to-severe Versus Mild Influenza in Children

Overview
Publisher Springer
Date 2016 Apr 18
PMID 27086364
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Some studies have assessed the efficacy of influenza vaccination in children separately for moderate-to-severe and any influenza, but the definition used for identifying children with moderate-to-severe illness has not been validated. We analyzed clinical and socioeconomic data from two prospective cohort studies of respiratory infections among children aged ≤13 years (four influenza seasons, 3,416 child-seasons of follow-up). We categorized children with laboratory-confirmed influenza into two mutually exclusive groups of moderate-to-severe and mild influenza using the previously proposed criteria. We obtained the data for the analyses from structured medical records filled out by the study physicians and from daily symptom cards filled out by the parents. Of 434 cases of influenza, 217 (50 %) were classified as moderate-to-severe and 217 (50 %) as mild. The mean duration of fever was 4.0 days in children with moderate-to-severe influenza and 3.1 days in those with milder illness (P < 0.0001). Antibiotics were prescribed to 111 (51 %) children with moderate-to-severe and to ten (5 %) children with mild influenza (P < 0.0001). The rates of parental work absenteeism were 184 days per 100 children with moderate-to-severe influenza and 135 days per 100 children with mild influenza (P = 0.02). The corresponding rates of children's own absenteeism from day care or school were 297 and 233 days respectively per 100 children (P = 0.006). Categorization of children into groups with moderate-to-severe and mild influenza is meaningful, and it identifies children in whom the clinical and socioeconomic impact of influenza is highest. Illness severity should be considered when assessing influenza vaccine effectiveness in children.

Citing Articles

Influenza virus shedding and symptoms: Dynamics and implications from a multiseason household transmission study.

Morris S, Nguyen H, Grijalva C, Hanson K, Zhu Y, Biddle J PNAS Nexus. 2024; 3(9):pgae338.

PMID: 39246667 PMC: 11378077. DOI: 10.1093/pnasnexus/pgae338.


Caregiver Burden among Patients with Influenza or Influenza-like Illness (ILI): A Systematic Literature Review.

Vaghela S, Welch V, Sinh A, Di Fusco M Healthcare (Basel). 2024; 12(16).

PMID: 39201150 PMC: 11353737. DOI: 10.3390/healthcare12161591.


Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States.

Kommandantvold S, Chang S, Surinach A, Yau V, Best J, Zaraket H Infect Dis Ther. 2024; 13(9):2071-2087.

PMID: 39150658 PMC: 11343959. DOI: 10.1007/s40121-024-01027-9.


Importance of History Taking and Physical Examination Before Rapid Laboratory Test for Seasonal Influenza Virus: A Single-Center Multiple Logistic Analysis.

Tasaki Y, Yokoyama T, Yamamiya M, Takakuwa M, Toyama T, Wada T Cureus. 2024; 15(12):e50093.

PMID: 38186539 PMC: 10770768. DOI: 10.7759/cureus.50093.


Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review.

Blanchet Zumofen M, Frimpter J, Hansen S Pharmacoeconomics. 2022; 41(3):253-273.

PMID: 36515814 PMC: 9748403. DOI: 10.1007/s40273-022-01224-9.


References
1.
Heikkinen T, Tsolia M, Finn A . Vaccination of healthy children against seasonal influenza: a European perspective. Pediatr Infect Dis J. 2013; 32(8):881-8. DOI: 10.1097/INF.0b013e3182918168. View

2.
Salo H, Kilpi T, Sintonen H, Linna M, Peltola V, Heikkinen T . Cost-effectiveness of influenza vaccination of healthy children. Vaccine. 2006; 24(23):4934-41. DOI: 10.1016/j.vaccine.2006.03.057. View

3.
Belshe R, Edwards K, Vesikari T, Black S, Walker R, Hultquist M . Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007; 356(7):685-96. DOI: 10.1056/NEJMoa065368. View

4.
Heinonen S, Silvennoinen H, Lehtinen P, Vainionpaa R, Vahlberg T, Ziegler T . Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis. 2010; 51(8):887-94. DOI: 10.1086/656408. View

5.
Grohskopf L, Sokolow L, Olsen S, Bresee J, Broder K, Karron R . Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. MMWR Morb Mortal Wkly Rep. 2015; 64(30):818-25. PMC: 5779578. DOI: 10.15585/mmwr.mm6430a3. View